+44 20 8123 2220
info@marketpublishers.com

Sarcopenia - Pipeline Insight, 2021

https://marketpublishers.com/r/SCD70CE492BEN.html
Date: July 2021
Pages: 60
Price: US$ 1,500.00 (Single User License)
ID: SCD70CE492BEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Sarcopenia - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Sarcopenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Sarcopenia Understanding

Sarcopenia: Overview

Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increased adverse outcomes including falls, functional decline, frailty, and mortality. It occurs commonly as an age-related process in older people, influenced not only by contemporaneous risk factors, but also by genetic and lifestyle factors operating across the life course. It can also occur in mid-life in association with a range of conditions.

'Sarcopenia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sarcopenia pipeline landscape is provided which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report

embraces, in depth Sarcopenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The therapies under development are focused on novel approaches to treat/improve Sarcopenia.

Sarcopenia Emerging Drugs Chapters

This segment of the Sarcopenia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sarcopenia Emerging Drugs

Sarconeos: Biophytis

Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Preclinical data demonstrated that Sarconeos (BIO101) for the treatment of sarcopenia has beneficial effects on muscle function and increases muscle strength and mobility in animal models. It activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS).

Further product details are provided in the report……..

Sarcopenia: Therapeutic Assessment

This segment of the report provides insights about the different Sarcopenia drugs segregated based on following parameters that define the scope of the report, such as:

+44 20 8123 2220
info@marketpublishers.com

Major Players in Sarcopenia

There are approx. 12+ key companies which are developing the therapies for Sarcopenia. The companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase II include, Biophytis.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sarcopenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

+44 20 8123 2220
info@marketpublishers.com

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sarcopenia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sarcopenia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sarcopenia drugs.

Sarcopenia Report Insights

Sarcopenia Pipeline Analysis

Therapeutic Assessment

+44 20 8123 2220
info@marketpublishers.com

Unmet Needs

Impact of Drugs

Sarcopenia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Sarcopenia drugs?

How many Sarcopenia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sarcopenia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sarcopenia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Sarcopenia and their status?

What are the key designations that have been granted to the emerging drugs?

+44 20 8123 2220
info@marketpublishers.com

Key Players

Biophytis

Lipocine Inc.

Novartis

Oncocross

Dystrogen Therapeutics

Faraday Pharmaceuticals

ImmunoForge Inc.

Rejuvenate Biomed NV

Ridgeline Therapeutics LLC

ST Pharm Co Ltd

Vibe Pharmaceuticals

Key Products

Sarconeos

LPCN 1148

Bimagrumab

FDY 5301

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Executive Summary
Sarcopenia: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
Sarconeos: Biophytis
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..

Early Stage Products (Phase I)
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development

+44 20 8123 2220
info@marketpublishers.com

Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Sarcopenia Key Companies
Sarcopenia Key Products
Sarcopenia- Unmet Needs
Sarcopenia- Market Drivers and Barriers
Sarcopenia- Future Perspectives and Conclusion
Sarcopenia Analyst Views
Sarcopenia Key Companies
Appendix

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1 Total Products for Sarcopenia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Sarcopenia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

I would like to order

Product name: Sarcopenia - Pipeline Insight, 2021
Product link: https://marketpublishers.com/r/SCD70CE492BEN.html
Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SCD70CE492BEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970